The highest dose of an experimental pill developed by Eli Lilly dramatically reduced an inherited form of high cholesterol in a mid-stage trial. The drug, muvalaplin, reduced levels of lipoprotein(a), or Lp(a), by 70 per cent using a traditional blood test and by nearly 86 per cent based on a more specific test developed by the company.